This content is in French.
Progressive MS: could the placenta pave the way?
30 mai 2025
#MultipleSclerosis #MS #CellTherapy
#Immunomodulation #Cytokines #Neuroinflammation
Multiple sclerosis (MS) is a chronic, progressive autoimmune disease of the central nervous system, primarily affecting young adults. It is characterized by persistent inflammation, demyelination of nerve fibers, and progressive axonal degeneration, which lead to a wide range of neurological symptoms. While relapsing forms of MS benefit from effective immunomodulatory treatments, the secondary progressive form (SPMS), which appears after several years, remains challenging to manage.
Multiple sclerosis (MS) is a chronic, progressive autoimmune disease of the central nervous system, primarily affecting young adults. It is characterized by persistent inflammation, demyelination of nerve fibers, and progressive axonal degeneration, which lead to a wide range of neurological symptoms. While relapsing forms of MS benefit from effective immunomodulatory treatments, the secondary progressive form (SPMS), which appears after several years, remains challenging to manage.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Shokati, A., et al. (2025). Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial. Scientific reports, 15(1), 16005
View the source
